loading
Cartesian Therapeutics Inc stock is traded at $16.87, with a volume of 7,216. It is up +1.06% in the last 24 hours and down -24.08% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
See More
Previous Close:
$16.94
Open:
$16.9
24h Volume:
7,216
Relative Volume:
0.07
Market Cap:
$430.53M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-51.37M
1W Performance:
+0.59%
1M Performance:
-24.08%
6M Performance:
-30.41%
1Y Performance:
-50.80%
1-Day Range:
Value
$16.80
$17.14
1-Week Range:
Value
$16.36
$19.85
52-Week Range:
Value
$11.66
$42.60

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
Name
Cartesian Therapeutics Inc
Name
Phone
301-348-8698
Name
Address
7495 NEW HORIZON WAY, FREDERICK
Name
Employee
38
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
RNAC 16.80 430.53M 26.00M -219.71M -51.37M 0.00
VRTX 447.51 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.12 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.20 24.49B 3.30B -501.07M 1.03B 11.54

Cartesian Therapeutics Inc Stock (RNAC) Latest News

pulisher
07:09 AM

Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire

07:09 AM
pulisher
05:23 AM

Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St

05:23 AM
pulisher
Nov 19, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Nigeria

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock - Investing.com

Nov 18, 2024
pulisher
Nov 17, 2024

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 17, 2024
pulisher
Nov 14, 2024

Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 13, 2024
pulisher
Nov 12, 2024

HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha

Nov 10, 2024
pulisher
Nov 09, 2024

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com

Nov 09, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 07, 2024

Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 05, 2024

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Cartesian's Novel mRNA CAR-T Therapy Data Selected for Major ASH Conference Spotlight | RNAC Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World

Nov 04, 2024
pulisher
Nov 01, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 01, 2024
pulisher
Oct 26, 2024

Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St

Oct 26, 2024
pulisher
Oct 18, 2024

Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance

Oct 18, 2024
pulisher
Oct 16, 2024

Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan

Oct 15, 2024
pulisher
Oct 13, 2024

Insider Buying Slows, but Not for These 7 Buyers - 24/7 Wall St.

Oct 13, 2024
pulisher
Oct 11, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN

Oct 06, 2024
pulisher
Oct 05, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa

Oct 05, 2024
pulisher
Oct 04, 2024

Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily

Oct 04, 2024
pulisher
Oct 03, 2024

Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 03, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Point72 Asia Singapore Pte. Ltd. Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Purchases Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Oct 01, 2024

Cartesian Therapeutics Inc Stock (RNAC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):